Introduction

Pharmacovigilance: Second Edition

Volumn , Issue , 2007, Pages 1-11

  Mann, Ronald D ^a   Andrews, Elizabeth B ^b,c  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b RTI HEALTH SOLUTIONS   (United States)

^c IL   (United States)

Author keywords

Adverse drug reactions (ADRs); Drug disasters thalidomide tragedy; Pharmacoepidemiology; Pharmacovigilance and marketed drugs safety; Prescription Drug User Fee Act (PDUFA)

Indexed keywords

EID: 78651243675     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470059210.ch1     Document Type: Editorial

References (17)

1. Herbst AL, Poskanzer DC, Robboy SJ et al. (1975) Prenatal exposure to stilbestrol. A prospective comparison of exposed female offspring with unexposed controls. N Engl J Med 292: 334-9.
2. Herbst AL, Robboy SJ, Scully RE, Poskanzer DC (1974) Clear-cell adenocarcinoma of the vagina and cervix in girls: analysis of 170 registry cases. Am J Obstet Gynecol 119: 713-24.
3. Hurwitz ES, Barrett MJ, Bregman D et al. (1987) Public Health Service study of Reye's syndrome and medications. Report of the main study [erratum in JAMA 257(24): 3366]. JAMA 257(14): 1905-11.
4. Institute of Medicine (1999) To Err is Human: Building a Safer Health System. Washington, DC: National Academy Press.
5. International Society for Pharmacoepidemiology (2004) Guidelines for Good Pharmacoepidemiology Practices (GPP), http://www.pharmacoepi.org/resources/guide lines_08027.cfm.
6. Lazarou JB, Pomeranz H, Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA 279: 1200-5.
7. Mann RD (1984) Modern Drug Use-An Enquiry on Historical Principles. Lancaster, UK: MTP Press (Kluwer Academic), pp. 597-619.
8. Mann RD (1987) The yellow card data: The nature and scale of the adverse drug reactions problem. In: Mann RD, ed., Adverse Drug Reactions. Carnforth, UK: Parthenon Publishing, pp. 59-63.
9. Pouyanne P, Haramburu F, Imbs JL, Begaud B for the French Pharmacovigilance Centres (2000) Admissions to hospital caused by adverse drug reactions: Cross sectional incidence study. BMJ 320: 1036.
10. Rawlins MD, Jefferys DB (1991) Study of United Kingdom product licence applications containing new active substances, 1987-89. BMJ 302: 223-5.
11. United States General Accounting Office (2000) Adverse Drug Events: The Magnitude of Health Risk is Uncertain Because of the Limited Incidence Data. Report GAO/HEHS-00-21. Washington, DC: US General Accounting Office.
12. U.S. Food and Drug Administration (1999) Managing the Risks from Medical Product Use: Creating a Risk Management Framework. Washington, DC: U.S. Food and Drug Administration, http://www.fda.gov/oc/ tfrm/riskmanagement.pdf.
13. U.S. Food and Drug Administration (2005a) Guidance for Industry E2E Pharmacovigilance Planning, http://www. fda.gov/cder/guidance/6355fnl.htm.
14. U.S. Food and Drug Administration (2005b) Guidance for Industry Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessments, http://www.fda.gov/cder/guidance/6359OCC.htm.
15. U.S. Food and Drug Administration (2005c) Guidance for Industry Development and Use of Risk Minimization Action Plans, http://www.fda.gov/cder/guidance/6358fnl.htm.
16. Werler MM, Shapiro S, Mitchell AA (1993) Periconceptional folic acid exposure and risk of occurrent neural tube defects. JAMA 269(10): 1257-61.
17. Wood AJ, Stein CM, Woosley RL (1998) Making medicines safer-the need for an independent drug safety board. N Engl J Med 339: 1851-4.